menu
    • menu
    [{"orgOrder":0,"company":"Indian Council of Medical Research","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Indian Council of Medical Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indian Council of Medical Research \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Indian Council of Medical Research \/ Inapplicable"},{"orgOrder":0,"company":"Indian Council of Medical Research","sponsor":"Bharat Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"BBV152","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Indian Council of Medical Research","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Indian Council of Medical Research \/ Indian Council of Medical Research","highestDevelopmentStatusID":"15","companyTruncated":"Indian Council of Medical Research \/ Indian Council of Medical Research"},{"orgOrder":0,"company":"Indian Council of Medical Research","sponsor":"Bharat Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"BBV152","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Indian Council of Medical Research","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indian Council of Medical Research \/ Indian Council of Medical Research","highestDevelopmentStatusID":"15","companyTruncated":"Indian Council of Medical Research \/ Indian Council of Medical Research"},{"orgOrder":0,"company":"Indian Council of Medical Research","sponsor":"Bharat Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"BBV152","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Indian Council of Medical Research","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Indian Council of Medical Research \/ Bharat Biotech","highestDevelopmentStatusID":"7","companyTruncated":"Indian Council of Medical Research \/ Bharat Biotech"},{"orgOrder":0,"company":"Indian Council of Medical Research","sponsor":"Bharat Biotech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"BBV152","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Indian Council of Medical Research","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Indian Council of Medical Research \/ Indian Council of Medical Research","highestDevelopmentStatusID":"15","companyTruncated":"Indian Council of Medical Research \/ Indian Council of Medical Research"},{"orgOrder":0,"company":"Indian Council of Medical Research","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nirmatrelvir","moa":"||SARS coronavirus 3C-like proteinase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Indian Council of Medical Research","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Indian Council of Medical Research \/ Indian Council of Medical Research","highestDevelopmentStatusID":"15","companyTruncated":"Indian Council of Medical Research \/ Indian Council of Medical Research"},{"orgOrder":0,"company":"Indian Council of Medical Research","sponsor":"University of Oxford","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Indian Council of Medical Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Indian Council of Medical Research \/ University of Oxford","highestDevelopmentStatusID":"1","companyTruncated":"Indian Council of Medical Research \/ University of Oxford"},{"orgOrder":0,"company":"Indian Council of Medical Research","sponsor":"Zydus Lifesciences","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Desidustat","moa":"enzyme inhibitors: hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitors","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Indian Council of Medical Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indian Council of Medical Research \/ Indian Council of Medical Research","highestDevelopmentStatusID":"8","companyTruncated":"Indian Council of Medical Research \/ Indian Council of Medical Research"},{"orgOrder":0,"company":"Indian Council of Medical Research","sponsor":"Aurigene Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"INDIA","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Indian Council of Medical Research","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indian Council of Medical Research \/ Indian Council of Medical Research","highestDevelopmentStatusID":"4","companyTruncated":"Indian Council of Medical Research \/ Indian Council of Medical Research"},{"orgOrder":0,"company":"Indian Council of Medical Research","sponsor":"Indian Council of Medical Research","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Granulocyte Colony-Stimulating Factor","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Undisclosed","graph3":"Indian Council of Medical Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indian Council of Medical Research \/ Indian Council of Medical Research","highestDevelopmentStatusID":"1","companyTruncated":"Indian Council of Medical Research \/ Indian Council of Medical Research"},{"orgOrder":0,"company":"Indian Council of Medical Research","sponsor":"Indian Council of Medical Research","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Umbilical Cord Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Indian Council of Medical Research","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indian Council of Medical Research \/ Indian Council of Medical Research","highestDevelopmentStatusID":"10","companyTruncated":"Indian Council of Medical Research \/ Indian Council of Medical Research"},{"orgOrder":0,"company":"Indian Council of Medical Research","sponsor":"Indian Council of Medical Research","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Umbilical Cord Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Indian Council of Medical Research","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indian Council of Medical Research \/ Indian Council of Medical Research","highestDevelopmentStatusID":"10","companyTruncated":"Indian Council of Medical Research \/ Indian Council of Medical Research"},{"orgOrder":0,"company":"Indian Council of Medical Research","sponsor":"Indian Council of Medical Research","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Umbilical Cord Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Indian Council of Medical Research","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indian Council of Medical Research \/ Indian Council of Medical Research","highestDevelopmentStatusID":"10","companyTruncated":"Indian Council of Medical Research \/ Indian Council of Medical Research"}]

    Find Clinical Drug Pipeline Developments & Deals by Indian Council of Medical Research

    Menu

    Indian Council of Medical Research

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Indian Council of Medical Research

                            India arrow
                            ESCRS
                            Not Confirmed

                            Indian Council of Medical Research

                            India arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Granulocyte Colony-Stimulating Factor

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Undisclosed

                            Recipient : Institute of Liver and Biliary Sciences, India

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            GCSF & Darbepoetin Single vs Repeated Cycle in Early Cirrhosis

                            Details : Granulocyte Colony-Stimulating Factor is a Protein drug candidate, which is currently being evaluated in clinical studies for the treatment of Liver Cirrhosis.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            August 20, 2025

                            Lead Product(s) : Granulocyte Colony-Stimulating Factor

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Undisclosed

                            Recipient : Institute of Liver and Biliary Sciences, India

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Indian Council of Medical Research

                            India arrow
                            ESCRS
                            Not Confirmed

                            Indian Council of Medical Research

                            India arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Umbilical Cord Mesenchymal Stem Cell

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase II

                            Recipient : Institute of Liver and Biliary Sciences, India

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MSC Therapy Safety & Efficacy In Non-Viral ACLF Patients (NC-CHRM Phase II)

                            Details : Umbilical Cord Mesenchymal Stem Cell is a Cell and Gene Therapy drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Acute-On-Chronic Liver Failure.

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            August 20, 2025

                            Lead Product(s) : Umbilical Cord Mesenchymal Stem Cell

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase II

                            Recipient : Institute of Liver and Biliary Sciences, India

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Indian Council of Medical Research

                            India arrow
                            ESCRS
                            Not Confirmed

                            Indian Council of Medical Research

                            India arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Umbilical Cord Mesenchymal Stem Cell

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase I

                            Recipient : Institute of Liver and Biliary Sciences, India

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MSC Therapy Safety & Efficacy In Non-Viral ACLF Patients (NC-CHRM Phase I)

                            Details : Umbilical Cord Mesenchymal Stem Cell is a Cell and Gene Therapy drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Acute-On-Chronic Liver Failure.

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            August 20, 2025

                            Lead Product(s) : Umbilical Cord Mesenchymal Stem Cell

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase I

                            Recipient : Institute of Liver and Biliary Sciences, India

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Indian Council of Medical Research

                            India arrow
                            ESCRS
                            Not Confirmed

                            Indian Council of Medical Research

                            India arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Umbilical Cord Mesenchymal Stem Cell

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase III

                            Recipient : Institute of Liver and Biliary Sciences, India

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MSC Therapy Safety & Efficacy In Non-Viral ACLF Patients (NC-CHRM Phase III)

                            Details : Umbilical Cord Mesenchymal Stem Cell is a Cell and Gene Therapy drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Acute-On-Chronic Liver Failure.

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            July 20, 2025

                            Lead Product(s) : Umbilical Cord Mesenchymal Stem Cell

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase III

                            Recipient : Institute of Liver and Biliary Sciences, India

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Indian Council of Medical Research

                            India arrow
                            ESCRS
                            Not Confirmed

                            Indian Council of Medical Research

                            India arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Desidustat

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Recipient : Zydus Lifesciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Zydus and ICMR Start Phase 2 Desidustat Trial in Sickle Cell Disease

                            Details : Rytstat (desidustat), first-of-its-kind oral tablet being investigated for the treatment for Sickle Cell Disease, in India.

                            Product Name : Oxemia

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 14, 2024

                            Lead Product(s) : Desidustat

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Recipient : Zydus Lifesciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Indian Council of Medical Research

                            India arrow
                            ESCRS
                            Not Confirmed

                            Indian Council of Medical Research

                            India arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Aurigene Oncology

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            ICMR partners with industry leaders for groundbreaking First-in-Human Phase-1 cl ..

                            Details : Under the partnership, ICMR will engage in collaborative research on a small molecule for multiple myeloma with Aurigene oncology.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            September 14, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Aurigene Oncology

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Indian Council of Medical Research

                            India arrow
                            ESCRS
                            Not Confirmed

                            Indian Council of Medical Research

                            India arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nirmatrelvir,Ritonavir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Recipient : Pfizer Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            No Merit Seen in Including Paxlovid in Covid Treatment: ICMR

                            Details : Paxlovid (nirmatrelvir) is an orally bioavailable protease inhibitor that is active against MPRO, a viral protease that plays an essential role in viral replication by cleaving the 2 viral polyproteins.

                            Product Name : Paxlovid

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 05, 2022

                            Lead Product(s) : Nirmatrelvir,Ritonavir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Recipient : Pfizer Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Indian Council of Medical Research

                            India arrow
                            ESCRS
                            Not Confirmed

                            Indian Council of Medical Research

                            India arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Baricitinib

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : University of Oxford

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Call for Expression of Intent to Participate as a Study Site for India-UK RECOVERY

                            Details : Baricitinib will only be included in the randomisation of women of child-bearing potential if they have had a negative pregnancy test since admission.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 14, 2021

                            Lead Product(s) : Baricitinib

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : University of Oxford

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Indian Council of Medical Research

                            India arrow
                            ESCRS
                            Not Confirmed

                            Indian Council of Medical Research

                            India arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BBV152

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Recipient : Bharat Biotech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Covid-19: Bharat Biotech Begins Phase 3 Trials of Covaxin in India

                            Details : India’s first phase 3 efficacy study for a Covid-19 vaccine, and the largest phase III efficacy trial ever conducted in India. Trial volunteers will receive two intramuscular injections of Covaxin, about 28 days apart.

                            Product Name : Covaxin

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            November 17, 2020

                            Lead Product(s) : BBV152

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Recipient : Bharat Biotech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Indian Council of Medical Research

                            India arrow
                            ESCRS
                            Not Confirmed

                            Indian Council of Medical Research

                            India arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Convalescent Plasma Misses the Mark in Phase 2 Trial

                            Details : The study results showed that Convalescent plasma was not associated with a reduction in progression to severe covid-19 or all cause mortality.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            October 22, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth